Chester County News and Community Website
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS this week announced a delay in the release of Phase III study data for its promising Parkinson’s Disease drug, buntanetap. The postponement …
Annovis Bio Postpones Release of Phase III Data for Parkinson’s Disease Drug, Buntanetap Read More
MALVERN, PA — In a strategic move that underscores its nearly two-decade legacy of innovation in the clinical trial space, YPrime this week announced a comprehensive brand evolution initiative. The …
YPrime Unveils Bold Brand Evolution, Aiming to Streamline and Accelerate Clinical Trials Read More
YARDLEY, PA — Optinose (NASDAQ: OPTN), a Pennsylvania-based pharmaceutical company, has announced the publication of results from its ReOpen1 and ReOpen2 clinical trials. The findings, published in the reputable Journal …
Optinose’s XHANCE Shows Significant Promise in Chronic Sinusitis Treatment: A Breakthrough Revealed in ReOpen Clinical Trials Read More
BLUE BELL, PA — Mitochon Pharmaceuticals recenlty secured approval from the European Medicines Agency (EMA) to initiate a pioneering Phase I/IIa biomarker study, marking a significant milestone in the fight …
Mitochon Pharmaceuticals Embarks on Groundbreaking Clinical Trial Targeting Four Neurodegenerative Diseases Read More
WAYNE, PA — Neuraptive Therapeutics, Inc., a Pennsylvania-based biotech company, recently announced a major breakthrough in the treatment of peripheral nerve injuries. The firm’s successful demonstration of proof-of-concept in the …
Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment Read More
NEWTOWN, PA — Helius Medical Technologies, Inc. (Nasdaq: HSDT) has announced an expansion of its registrational program with the addition of Brooks Rehabilitation Hospital. This strategic alliance is expected to …
Helius Medical Technologies Expands Stroke Program, Investors Eye Potential Returns Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …
Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence Read More
HORSHAM, PA — In the realm of dermatology, a breakthrough could be on the horizon. STRATA Skin Sciences, Inc. (NASDAQ: SSKN) recently unveiled encouraging results of a clinical study into …
STRATA Skin Sciences Unveils Promising Acne Treatment, A Potential Game-Changer for Investors Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) this week outlined its business outlook for 2024, highlighting upcoming clinical milestones and a robust financial position that could make it an …
Arbutus Biopharma: Promising Clinical Trials and Patent Litigation Could Drive Investor Interest in 2024 Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced the first patient was randomized in its BACKBEAT pivotal study in late December 2023. This marks a significant …
Orchestra BioMed’s Bioelectronic Therapy Pivotal Study Begins: A Potential Game-Changer for Hypertensive Patients Read More